UK IgA Nephropathy Competitive Intelligence

An estimated 10,000-15,000 UK IgA Nephropathy patients are managed within a well-established NHS renal biopsy network of roughly 80 specialist nephrology centres; the UK Renal Registry tracks approximately 8,000 diagnosed cases. Kidney biopsy is required for diagnosis under Renal Association guidelines (UPCR >0.1g/mmol with unexplained haematuria), and ACE inhibitor/ARB optimisation to target blood pressure <130/80 and UPCR <0.5g/g is NHS standard of care before novel agent consideration — a structural 3-6 month delay gate ahead of eligibility for either novel therapy.

Both budesonide (Tarpeyo, Calliditas/AstraZeneca) and sparsentan (Filspari, Travere) are accessed via Named Patient Programme at UK nephrology centres while their NICE technology appraisals progress. Because IgA Nephropathy prevalence is too high for the ultra-rare NICE Highly Specialised Technology track, both will be appraised under the standard TA process at the standard £20,000-30,000/QALY threshold — a materially harder bar than the £100,000-300,000/QALY threshold used for genuinely ultra-rare conditions. Both manufacturers will need to model end-stage renal disease cost offsets (dialysis at roughly £37,000/year; transplant at £22,000-40,000 in year one) convincingly to clear NICE's cost-effectiveness requirement.

Every AXLRx brief is built from primary regulatory sources (MHRA, EMA, NICE), peer-reviewed literature, and NHS commissioning documentation — not secondary summaries. Findings are independently verified before inclusion.

IgA Nephropathy UK CI sources: NefIgArd trial results, PROTECT trial results, UK Renal Registry annual report 2023, NICE evidence scope documentation for IgA Nephropathy therapies, Renal Association IgA Nephropathy guideline 2023, and NHS PbR tariff 2023-24 renal cost data.